Reducing Surgical Complications in Newly Diagnosed Lung Cancer Patients Who Smoke Cigarettes
Principal Investigator (?)
Study Number
A211401
Summary
This randomized phase III trial studies how well management of a tobacco treatment
intervention works in reducing surgical complications in patients with newly diagnosed lung
cancer who smoke cigarettes. Management of a tobacco treatment intervention compares
varenicline (a drug that reduces the craving and withdrawal symptoms that occur with
abstinence from nicotine) and behavioral interventions (consisting of a brief
clinician-delivered intervention and tobacco quitline [tobacco cessation service available
through a toll-free telephone number] follow-up) with placebo (a pill with no active
medication) along with similar behavioral interventions. It is not yet known whether
management of a tobacco treatment intervention is more effective in reducing surgical
complications than placebo.
Phase (?)
Phase III
Sponsor (?)
Alliance - NCI Cooperative Group
Available at the following location(s)
Lebanon
Contact Information
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
- Cancer Help Line: (800) 639-6918
- Email: cancer.research.nurse@dartmouth.edu
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.